Screening for the serum differential proteins of renal cell carcinoma using magnetic beads-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

Acta Academiae Medicinae Sinicae

Volumn 33, Issue 3, 2011, Pages 287-291

  Liu, Jin Shun ^a   Li, Han Zhong ^a   Zhang, Yu Shi ^a   Wang, Peng ^a   Yan, Wei Gang ^a   Xie, Jing ^a   Dong, De Xin ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Magnetic beads; Matrix assisted laser desorption ionization time of flight mass spectrometry; Renal cell carcinoma

Indexed keywords

PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; KIDNEY CARCINOMA; KIDNEY INJURY; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BLOOD PROTEINS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 79960907920     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: 10.3881/j.issn.1000-503X.2011.03.016     Document Type: Article

References (13)

1. Banks RE, Craven RA, Hamden P, et al. Key clinical issues in renal cancer: a challenge for proteomics [J]. World J Urol, 2007, 25(6):537-556.
2. Tolson J, Bogumil R, Brunst E, et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients [J]. Lab Invest, 2004, 84(7):845-856.
3. Engwegen JY, Mehra N, Haanen JB, et al. Validation of SELDI-TOF-MS serum protein profiles for renal cell carcinoma in new populations [J]. Lab Invest, 2007, 87(2):161-172.
4. Holcakova J, Hernychova L, Bouchal P, et al. Identification of alphaB- crystallin, a biomarker of renal cell carcinoma by SELDI-TOF-MS [J]. Int J Biol Markers, 2008, 23 (1):48-53.
5. Jones J, Otu HH, Grall F, et al. Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer [J]. J Urol, 2008, 179(2):730-736.
6. Nakamura K, Yoshikawa K, Yamada Y, et al. Differential profiling analysis of proteins involved in anti-proliferative effect of interferon-alpha on renal cell carcinoma cell lines by protein biochip technology [J]. Int J Oncol, 2006, 28 (4):965-970.
7. Sparbier K, Asperger A, Resemann A, et al. Analysis of glycoproteins in human serum by means of glycospecific magnetic bead separation and LC-MALDI-TOF/TOF analysis with automated glycopeptide detection [J]. J Biomol Tech, 2007, 18(4):252-258.
8. Ducoux-Petit M, Uttenweiler-Joseph S, Brichory F, et al. Scaled-down purification protocol to access proteomic analysis of 20S proteasome from human tissue samples: comparison of normal and tumor colorectal cells [J]. J Proteome Res, 2008, 7(7):2852-2859.
9. Freed GL, Cazares LH, Fichandler CE, et al. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples [J]. Laryngoscope, 2008, 118(1):61-68.
10. Engwegen JY, Gast MC, Schellens JH, et al. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry [J]. Trends Pharmacol Sci, 2006, 27(5):251-259.